CD19 CAR T cell product and disease attributes predict leukemia remission durability

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia

(2016) Nathan Singh et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The development of targeted new agents to improve the outcome for children with leukemia

(2016) Francisco Bautista et al.   Expert Opinion on Drug Discovery

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

The epigenetic landscape of T cell exhaustion

(2016) D. R. Sen et al.   SCIENCE

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

(2016) Nathan Singh et al.   Science Translational Medicine

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

(2016) Yarne Klaver et al.   Frontiers in Immunology

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation

(2016) Justyna Ogonek et al.   Frontiers in Immunology

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory

(2015) Giacomo Oliveira et al.   Science Translational Medicine

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy

(2015) Michael A. Huang et al.   Journal of Immunology Research

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells

(2014) C. Berger et al.   Cancer Immunology Research

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

(2010) X. Wang et al.   BLOOD

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION